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Glaucoma spectrum and age-related prevalence of
individuals with FOXC1 and PITX2 variants
Emmanuelle Souzeau*,1, Owen M Siggs1, Tiger Zhou1, Anna Galanopoulos2, Trevor Hodson3,
Deepa Taranath1, Richard A Mills1, John Landers1, John Pater1, James E Smith4,5,6, James E Elder7,8,
Julian L Rait9,10, Paul Giles11, Vivek Phakey12, Sandra E Stafﬁeri7,9,10, Lisa S Kearns9,10, Andrew Dubowsky13,
David A Mackey14,15, Alex W Hewitt9,10,15, Jonathan B Ruddle7,9,10, Kathryn P Burdon1,15 and Jamie E Craig1
Variation in FOXC1 and PITX2 is associated with Axenfeld-Rieger syndrome, characterised by structural defects of the anterior
chamber of the eye and a range of systemic features. Approximately half of all affected individuals will develop glaucoma,
but the age at diagnosis and the phenotypic spectrum have not been well deﬁned. As phenotypic heterogeneity is common,
we aimed to delineate the age-related penetrance and the full phenotypic spectrum of glaucoma in FOXC1 or PITX2 carriers
recruited through a national disease registry. All coding exons of FOXC1 and PITX2 were directly sequenced and multiplex
ligation-dependent probe ampliﬁcation was performed to detect copy number variation. The cohort included 53 individuals from
24 families with disease-associated FOXC1 or PITX2 variants, including one individual diagnosed with primary congenital
glaucoma and ﬁve with primary open-angle glaucoma. The overall prevalence of glaucoma was 58.5% and was similar for both
genes (53.3% for FOXC1 vs 60.9% for PITX2, P=0.59), however, the median age at glaucoma diagnosis was signiﬁcantly lower
in FOXC1 (6.0±13.0 years) compared with PITX2 carriers (18.0±10.6 years, P=0.04). The penetrance at 10 years old was
signiﬁcantly lower in PITX2 than FOXC1 carriers (13.0% vs 42.9%, P=0.03) but became comparable at 25 years old (71.4%
vs 57.7%, P=0.38). These ﬁndings have important implications for the genetic counselling of families affected by Axenfeld-
Rieger syndrome, and also suggest that FOXC1 and PITX2 contribute to the genetic architecture of primary glaucoma subtypes.
European Journal of Human Genetics (2017) 25, 839–847; doi:10.1038/ejhg.2017.59; published online 3 May 2017
INTRODUCTION
Anterior segment dysgenesis is a heterogeneous group of develop-
mental disorders affecting the anterior structures of the eye.1 Axenfeld-
Rieger malformation (ARM) represents a subgroup of anterior
segment dysgenesis and refers to congenital ocular features including
abnormal angle tissue, iris stromal hypoplasia, pseudopolycoria
(additional pupillary opening in the iris), corectopia (displaced pupil),
posterior embryotoxon (thickened and centrally displaced Schwalbe’s
line) and/or peripheral anterior synechiae (irido-corneal adhesions).2,3
A range of systemic features can also be present as part of the
Axenfeld-Rieger syndrome (ARS), with the most common including
facial dysmorphism, dental anomalies, periumbilical skin, cardiac
defects and hearing loss.3,4 The presence of anomalies in the anterior
chamber angle and drainage structures of the eye contribute to a
lifetime risk of developing glaucoma and can lead to irreversible
blindness,5 although the severity of the anomalies does not seem to
correlate well with the age at diagnosis, the severity or the progression
of glaucoma.5 It is usually reported that ~ 50% of individuals with
ARM will develop glaucoma, with an age of onset ranging from birth
to late in adulthood.5 Guidelines for appropriate follow-up strategies
for affected individuals without glaucoma lack a clear evidence base.
ARS is genetically heterogeneous. Deleterious sequence variants in
the FOXC1 (6p25.3, MIM 601090)6,7 and PITX2 genes (4q25, MIM
601542),8 as well as two additional loci (RIEG2 at 13q14 and
16q24),9,10 have been associated with ARS. In addition, several copy
number variants and chromosomal rearrangements disrupting FOXC1
or PITX2 have been reported in association with ARS.11–14 Deleterious
variants in both genes account for approximately 40% of individuals
with ARS,11,15 with inter- and intra-familial variable expressivity
frequently reported.16,17 Although the ARM ocular phenotype asso-
ciated with variants in FOXC1 and PIXT2 is thought to be highly
penetrant and undistinguishable between both genes, there is a
variable expressivity of systemic features. Variants in PITX2 are more
often associated with dental and/or umbilical anomalies, whereas
individuals with FOXC1 variants often have the ARM phenotype
alone, or display a range of other systemic anomalies including heart
anomalies, hearing defects, developmental delay and/or growth
delay.11,15,18 In addition, FOXC1 has recently been identiﬁed as a
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primary open-angle glaucoma (POAG) susceptibility locus19 and an
essential regulator of lymphangiogenesis.20
FOXC1 encodes a forkhead transcription factor encoded by a single
exon, whereas PITX2 is a member of a paired class of homeodomain
transcription factors and encodes four alternative transcripts (PITX2A,
B, C and D). Both are expressed during embryonic development and
regulate downstream genes important for cell differentiation and
migration via DNA binding. FOXC1 and PITX2 are co-expressed in
the periocular mesenchyme and can physically interact with each
other via their C-terminal domain and their homeobox domain,
respectively.21 PITX2 can inhibit the transactivation activity of FOXC1,
which is lost in the presence of PITX2 loss-of-function variants.21 The
transcriptional activity of both genes requires tight regulation during
embryogenesis for proper development of anterior segment tissues.
Although the morphological ocular anomalies associated with
FOXC1 and PITX2 variants have been well described, the spectrum
and prevalence of glaucoma in mutation carriers have not been well
characterised. In this study, we delineated the glaucoma prevalence
and phenotype in a cohort of patients diagnosed with ARM and their
family members with FOXC1 and PITX2 variants.
METHODS
Participants’ recruitment
Ethics approval was obtained from the Southern Adelaide Clinical Human
Research Ethics Committee. The study was conducted in accordance with the
revised Declaration of Helsinki. Individuals were recruited through the
Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG) as
described previously.22 Informed written consent and a blood or saliva sample
for DNA extraction purposes were obtained. Clinical information was collected
by the patient’s usual treating ophthalmologist. The feedback of results and
genetic counselling was provided to the participants.
Individuals with ARM recruited in the ANZRAG were tested for the FOXC1
and PITX2 genes. Family members of individuals with variants in these genes
were offered genetic testing. The cohort included all ARM probands and their
family members identiﬁed as having a deleterious variant in the FOXC1 or the
PITX2 genes. The diagnoses of ARM and glaucoma were made by the treating
specialist who referred the patient to the ANZRAG. Individuals with ARM were
recruited in the ANZRAG regardless of their glaucoma status. Advanced
glaucoma was deﬁned as visual ﬁeld loss in the worse eye related to glaucoma
with at least two out of the four central ﬁxation squares having a pattern
standard deviation o0.5% on a reliable Humphrey 24-2 ﬁeld, or a mean
deviation of o− 22 dB. Ocular hypertension was deﬁned by an intraocular
pressure ⩾ 21 mm Hg.
Genetic testing
FOXC1 and PITX2 genetic testing was performed through the NATA (National
Association of Testing Authorities) accredited laboratories of SA Pathology
at the Flinders Medical Centre (Bedford Park, SA, Australia). Venous blood
specimens were collected into EDTA tubes; genomic DNA was prepared from a
200 μl sample of blood and extracted by a QIAcube automated system using
QIAamp DNA Blood Mini kit (Qiagen, Chadstone, VIC, Australia) reagents
according to the manufacturer protocols. Saliva specimen were collected into an
Oragene•DNA Self-Collection Kit (DNA Genotek Inc., Ottawa, ON, Canada)
and the DNA was isolated from 500 μl of sample and extracted as described in
the manufacturer’s instructions. The entire coding sequence and intron exon
boundaries of FOXC1 and PITX2 were ampliﬁed as overlapping fragments in
separate reactions with primer pairs (Supplementary Table 1).
Each polymerase chain reaction (PCR) was prepared using 100 ng of puriﬁed
genomic DNA as template, 0.5 μM of each primer and a 1× concentration of
AmpliTaq Gold 360 Master Mix (Thermo Fisher Scientiﬁc, Scoresby, VIC,
Australia); 2.5 μl of 360 GC Enhancer (Thermo Fisher Scientiﬁc) was added to
each PITX2 reaction mix, and 5 μl to each FOXC1 reaction mix. All reactions
were adjusted to a ﬁnal volume of 25 μl with deionised water. Gene template
targets were ampliﬁed in a Veriti thermal cycler (Thermo Fisher Scientiﬁc)
using separate conditions for each gene; FOXC1: Step 1, 95 ˚C for 10 min; Step
2, 95˚C for 30 s, 55 ˚C for 30 s, 72 ˚C for 30 s, repeated for 40 cycles; Step 3,
72 ˚C for 7 min. PITX2: Step 1, 94 ˚C for 5 min; Step 2, 94 ˚C for 30 s, 61 ˚C
for 30 s (decreasing after ﬁve cycles by 1 ˚C every ﬁve cycles), 72 ˚C for 1 min,
repeated for 15 cycles; Step 3, 94 ˚C for 30 sec, 58 ˚C for 50 s, 72 ˚C for 1 min,
repeated for 35 cycles; Step 4, 72 ˚C for 10 min.
PCR ampliﬁed products were prepared for DNA sequencing by the 'ExoSAP'
method using a 10 μl sample of each PCR reaction treated with 5 U of
Exonuclease I (Biolabs, Ipswich, MA, USA) and 1 U of shrimp alkaline
phosphatase (USB Corporation, Cleveland, OH, USA) to remove residual
primers and dNTPs. Bi-directional BigDye Terminator Cycle Sequencing
(Thermo Fisher Scientiﬁc) reactions of the appropriate template and FOXC1
and PITX2 PCR primers were resolved and base called on an Applied
Biosystems 3130xl Genetic Analyser (Thermo Fisher Scientiﬁc).
Detection of sequence variants was performed with the aid of the Mutation
Surveyor v4.0 (SoftGenetics LLC, State College, PA, USA) programme; all
forward and reverse sequence trace ﬁles were assembled by the programme
against the FOXC1 (NM_001453.2) and PITX2 (NM_153427.2) GenBank
reference. Signiﬁcant differences in the relative peak heights of the sequence
traces observed between that of the patient sample and a normal control were
automatically called as a sequence variant by Mutation Surveyor; all such calls
were visually inspected for conﬁrmation. The Sorting Intolerant From Tolerant
(SIFT; http://sift.jcvi.org) and PolyPhen-2 HumVar (http://genetics.bwh.har-
vard.edu/pph2) software programmes were used to predict the potential impact
of amino acid substitutions on the protein. Homologene (www.ncbi.nlm.nih.
gov/homologene) was used to assess the conservation among mammalian
species. Allelic frequencies were compared with the population frequencies
from the Exome Variant Server (EVS, http://evs.gs.washington.edu/EVS) and
the Exome Aggregation Consortium v0.3.1 (ExAC, http://exac.broadinstitute.
org). All variants are publically available at the ClinVar database (www.ncbi.
nlm.nih.gov/clinvar/; accession numbers SCV000494251-SCV000494276).
FOXC1 and PITX2 were analysed for copy number variation by multiplex
ligation-dependent probe ampliﬁcation (MLPA) using the SALSA MLPA P054-
B2 FOXL2-TWIST1 probemix (MRC Holland, Amsterdam, The Netherlands)
according to the manufacturer’s instructions. The copy number present in the
original DNA specimen was determined from the relative amplitude of each
amplicon product detected using the ABI 3130xl Genetic Analyzer, and the data
analysed using Peak Scanner v2.0 (Thermo Fisher Scientiﬁc). Breakpoints of the
genomic deletions and duplications that have been further characterised in
Clinical Genetics using SNP arrays have been added in Tables 1 and 2.
Statistical analysis
PASW Statistics, Rel. 18.0.1.2009 (SPSS Inc., Chicago, IL, USA) was used
for statistical analyses. Data are presented as median± standard deviation.
Fisher’s exact test and Mann–Whitney U-test were used for the assessment of
differences in non-parametric data.
RESULTS
The cohort consisted of 53 individuals from 24 families with
heterozygous FOXC1 or PITX2 variants. The pedigrees are depicted
in Figure 1. There were 25 males (47.2%) and 28 females (52.8%). The
majority were Caucasian (94.3%). The mean age of the participants
was 35.7± 20.4 years. Twenty probands (83%) had a family history of
ARM and/or glaucoma.
FOXC1 variants were present in 30 individuals (56.6%) compared
with 23 (43.4%) in PITX2. We identiﬁed 19 sequence variants across
both genes (Tables 1 and 2 and Figure 2), of which 15 were considered
novel (not reported in the literature and not present in the EVS or the
ExAC database). Four nonsense, eight frameshift and one splice site
sequence variants were considered to affect function. Among six
missense sequence variants identiﬁed, PITX2 p.(Pro64Leu) has pre-
viously been reported among different families as deleterious.23–26 The
other ﬁve missense sequence variants have not been reported before
and were absent from the EVS and the ExAC database. Sequence
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variants p.(Leu86Phe), p.(Ala90Thr) and p.(Thr153Pro) are located in
the forkhead domain of the FOXC1 gene which is important for DNA
binding. Both Polyphen-2 and SIFT predicted these sequence variants
to be damaging to the protein, with all three residues highly conserved
across different species (Supplementary Figure 1). Similarly, PITX2
variants p.(Arg91Gly) and p.(Ala92Pro) are located in the homeobox
domain, which is essential for binding to FOXC1,21 with both residues
highly conserved across different species (Supplementary Figure 1) and
predicted deleterious by Polyphen-2 and SIFT algorithms. As a result,
these ﬁve missense variants were also considered likely to be disease-
causing. Finally, we identiﬁed ﬁve copy number variants: one deletion
and one duplication of the FOXC1 gene, and three deletions of the
PITX2 gene. All encompassed the entire gene, apart from one PITX2
deletion, which spanned the last two coding exons.
In this cohort, 31 individuals (58.5%) had glaucoma, 6 (11.3%) had
ocular hypertension and 16 (30.2%) showed no sign of glaucoma
(Tables 1 and 2 and Supplementary Tables 2 and 3). Among the
individuals with glaucoma, 48.4% (15/31) had advanced glaucoma as
deﬁned by the ANZRAG visual ﬁeld criteria. The prevalence of
glaucoma did not differ between FOXC1 (16/30, 53.3%) and PITX2
carriers (14/23, 60.9%, P= 0.59), with the median age of glaucoma
diagnosis at 13.5± 12.2 years (range 0–48 years) for the entire cohort.
Median age at diagnosis was signiﬁcantly lower in FOXC1 compared
with PITX2 carriers (6.0± 13.0 years (range 0–37) vs 18.0± 10.6 years
(range 1–48), P= 0.04). The penetrance at 10 years of age was 29.4%
for the whole cohort and was signiﬁcantly higher for FOXC1 carriers
(42.9%) than PITX2 carriers (13.0%, P= 0.03). Penetrance at 25 years
was 63.8% for the whole cohort and was similar between both genes
(57.7% for FOXC1 carriers vs 71.4% for PITX2 carriers, P= 0.38). The
median age of individuals who did not have glaucoma was 29.5± 21.2
years (range 5–77 years) and was not signiﬁcantly different between
FOXC1 (34.0± 24.2 years, range 5–77) and PITX2 carriers (20.0± 13.1
years, range 17–46, P= 0.74).
As shown in Tables 1 and 2, there was inter- and intra-familial
phenotypic variability in ocular morphology and glaucoma type,
although glaucoma prevalence was not different between loss-of-
function variants, missense variants and copy number variants
(P= 0.72). Among the 53 individuals included in this study, 47
(88.7%) had classic ocular features of ARM (Figure 3). One family
member of an individual with ARM was diagnosed with primary
congenital glaucoma (PCG) and had mild features of ARM on re-
examination after genetic testing (1B). Five family members of
individuals with ARM had been diagnosed with POAG and had only
mild or no features of ARM on re-examination after genetic testing
(Figure 4). Four of the POAG cases had systemic features consistent
with ASD, three carried FOXC1 variants (11A, 6B, 13B) and two had
PITX2 variants (15A, 15C).
All individuals with PITX2 variants had dental and umbilical
anomalies including microdontia, hypodontia, redundant periumbili-
cal skin or umbilical hernia. Additional systemic features were present
in seven individuals and included Wolff–Parkinson–White syndrome,
cleft palate, imperforate anus, ﬁne motor skill delay, unilateral vas
deferens and epilepsy. In comparison with PITX2, the majority of
FOXC1 carriers (21/30, 70.0%, Po0.001) had no systemic features.
Among the FOXC1 carriers who did have systemic features, a range of
abnormalities were reported including hearing loss (3/30, 10.0%),
heart anomalies (3/30, 10.0%), short stature (2/30, 6.7%), club foot
(2/30, 6.7%), hydrocephalus (1/30, 3.3%), intellectual disability (1/30,
3.3%) and ﬁne motor skills delay (1/30, 3.3%).
DISCUSSION
In this study, we investigated the clinical phenotype of 53 ARM
probands and their family members with variants in FOXC1 or PITX2.
Glaucoma was present in 59% and ocular hypertension in an
additional 11%. Shields5 reported glaucoma in 58% of individuals
with a purely clinical diagnosis of ARM (with or without systemic
features), and glaucoma prevalence among ARS patients with FOXC1
or PITX2 variants has previously been estimated at between 35% and
Figure 1 Pedigrees of the families. Round symbols indicate females; square
symbols, males; black symbols, Axenfeld-Rieger Syndrome; grey symbols;
primary open-angle glaucoma, dashed symbols; primary congenital
glaucoma, unﬁlled symbols, unaffected; diagonal line, deceased; arrow,
proband; D, sperm donor; +/, presence/absence of the gene variant.
(a) Families with FOXC1 variants. (b) Families with PITX2 variants.
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75%.11,15,18 This is the ﬁrst study to investigate the age-related
glaucoma prevalence of each gene, along with the associated glaucoma
phenotype.
We found a similar prevalence of glaucoma between FOXC1 and
PITX2 carriers. Previous studies found a higher prevalence of
glaucoma among FOXC1 carriers than for PITX2 carriers.11,15,18 These
differences can be explained by the age at diagnosis of affected
individuals and the age of unaffected carriers reported. Although we
have identiﬁed similar rates of glaucoma between both genes, the
median age at diagnosis was signiﬁcantly younger for FOXC1 carriers
than for PITX2 carriers. Moreover, the prevalence at 25 years old was
similar between both genes but the prevalence at 10 years old was
signiﬁcantly higher for FOXC1 carriers than for PITX2 carriers. Our
results suggest that young unaffected individuals can still develop
glaucoma at a later age. As a result, previous studies that were skewed
toward PITX2 carriers15 or had young unaffected individuals11,15 had a
lower glaucoma prevalence than studies including a high proportion of
FOXC1 carriers.18 Our ﬁndings showed that although the prevalence
of glaucoma is similar between both genes, patients with FOXC1
variants are likely to develop glaucoma at a younger age than PITX2
carriers. In addition, our cohort included all available family members
who were found to carry the suspected deleterious variant, which
reduced the risk of recruitment bias.
In our study, one individual was initially diagnosed as PCG and ﬁve
as POAG by their referring ophthalmologist. On re-examination, the
individual with PCG and two individuals diagnosed with POAG had
mild irido-corneal adhesions, whereas one individual with POAG had
mild iris stromal hypoplasia. Two of the four FOXC1 carriers had
hearing loss and the other two PITX2 carriers had dental and/or
umbilical anomalies, none of which had been recorded before the
molecular diagnosis. Individuals with variants in FOXC1 or PITX2 but
without ocular features of ARS have been reported before,15,27,28 and
in some individuals ARM can be so mild that it results in a clinical
diagnosis of PCG or POAG. The variable expressivity associated with
FOXC1 and PITX2 variants can make clinical diagnosis of ARS
challenging, especially in the absence of ARM. However, all individuals
were part of families with ARM and four out of six had systemic
features consistent with ARS, emphasising the importance of delineat-
ing the systemic features associated with each gene to assist clinicians
in reaching a differential diagnosis. Our ﬁndings conﬁrmed that PITX2
variants are strongly associated with dental and umbilical anomalies,
whereas the majority (70%) of FOXC1 carriers lack systemic features;
however, our cohort is biased toward participants with ocular features.
In ARS, glaucoma is often challenging to treat and the intraocular
pressure difﬁcult to control, often requiring incisional surgery
(trabeculectomy or glaucoma drainage implant) and in some cases
repeated surgical procedures.5,18 Standard medications and surgical
procedures often have a lower success rate than in non-ARS glaucoma
patients.29 In our study, 48% of individuals with glaucoma had
advanced visual ﬁeld loss and all had incisional surgery. This highlights
the importance of early molecular diagnosis for effective monitoring
and treatment options.
Although the exact mechanism by which ARS causes glaucoma is
not fully understood, it is hypothesised that an arrested development
of the anterior chamber angle structures during gestation (charac-
terised by an incomplete maturation of the trabecular meshwork, an
absent or poorly developed Schlemm’s canal and/or a high insertion of
the iris) alters the aqueous humour ﬂow, thereby increasing intrao-
cular pressure and resulting in glaucoma.5 Broad phenotypic varia-
bility associated with FOXC1 and PITX2 variants has been reported
before,11,14,17,18 as it has in this study, although Shields5 previously
reported that the severity of ocular defects did not correlate with the
Figure 2 Distribution of the identiﬁed variants in the FOXC1 (a) and PITX2 proteins (b). Missense variants are underlined.
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development of glaucoma. FOXC1 and PITX2 both encode develop-
mental transcription factors expressed in a tightly regulated temporal
and spatial manner during development. Therefore, it is likely that
disruption to the protein expression or activity level might not be well
tolerated. However, inter- and intra-familial variability is often
reported,16,17,30 and is reﬂected by the variability in glaucoma
phenotype within the families described here. Clinical heterogeneity
of FOXC1 and PITX2 variants is likely to be explained by genetic
modiﬁers, as suggested by the differing ocular phenotypes of
Foxc1-deﬁcient mice on different genetic backgrounds.31 However,
these modiﬁers remain to be identiﬁed.
A limitation of the study is that not every family member was tested,
although all ﬁrst-degree relatives of mutation carriers were invited to
participate. Therefore, it is possible that individuals with milder
phenotypes exist in the population but were not included. In addition,
recruitment was somewhat biased towards glaucoma since participants
were part of an advanced glaucoma registry, although the registry
includes participants with ARM irrespective of their glaucoma status.
Finally, diagnoses were made by different treating specialists, which may
have introduced some variation in the phenotypic descriptions.
In conclusion, 59% of FOXC1 and PITX2 carriers in our cohort had
glaucoma. Variants in both genes were associated with a similar risk of
Figure 3 Clinical photographs of individuals with ocular features of Axenfeld-Rieger Malformation. Photographs in (a–c) showing the right eye (left panel) and the
left eye (right panel). (a) Slit lamp photos showing corectopia in the left panel, iris stromal hypoplasia in both eyes and posterior embryotoxon (black arrows) in both
eyes (individual 9B). (b) Slit lamp photos showing corectopia, pseudopolycoria (black arrows) and iris stromal hypoplasia in both eyes (individual 18B). (c) Slit lamp
photos showing corectopia and posterior embryotoxon (black arrows) in both eyes (individual 12). (d) Gonioscopy showing irido-corneal adhesions (black arrow, left
panel) and photo showing the presence of breaks in the Descemet’s membrane (Haab’s striae, white arrow, right panel; individual 5A).
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glaucoma, with FOXC1 carriers displaying an earlier age of onset than
PITX2 carriers. These ﬁndings have implications when counselling
individuals and their family members about their risk of developing
glaucoma following genetic testing results. Furthermore, one family
member was diagnosed with PCG and ﬁve with POAG, suggesting that
variants in FOXC1 and PITX2 may also contribute to the genetic
architecture of POAG and PCG. Further sequencing of large patient
cohorts will be needed to determine the contribution of these genes to
other glaucoma subtypes.
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